Fig. 3. Progression-free survival and overall survival according to telomerase activity (TA) and the interphase telomere lengths (TL). Time to progression to AML for patients with high (≥average) and low (<average) TA (A), long (≥average) and short (<average) interphase TL (B). The Kaplan Meier survival curve for patients with high and low TA (C), long and short interphase TL (D).
